PwPepwise

Thymosin Beta-15

Healing & Recovery

a.k.a. Tβ15

TB-4 analog

Thymosin Beta-15 (Tβ15) is a small protein belonging to the thymosin beta family, a group of molecules best known for their role in regulating actin.

§Dosing at a glance

1 protocol · from the research
What it's forDoseHow oftenHowFor how long
General protocol1 µg———

Approximate values pulled from the research — double-check before dosing.

§01Summary

Thymosin Beta-15 (Tβ15) is a small protein belonging to the thymosin beta family, a group of molecules best known for their role in regulating actin — the structural protein that gives cells their shape and enables them to move. Unlike its more widely studied relative Thymosin Beta-4, Tβ15 appears to play a particularly prominent role in controlling how cells migrate, a process central to both normal tissue development and cancer spread3,14. Research has identified Tβ15 as a regulator of thymic epithelial cell organization, suggesting it may influence the quality of immune cell development in the thymus6,7. In cancer biology, elevated Tβ15 gene expression has been reported to predict how well certain breast cancer patients respond to chemotherapy, particularly those with triple-negative breast cancer1,2. In prostate cancer, higher Tβ15 expression may serve as a marker of more aggressive disease and greater likelihood of spread3,9. Tβ15 has also been reported to exhibit pro-angiogenic activity in preclinical models, supporting blood vessel formation at relevant concentrations5. It is important to note that the current body of research positions Tβ15 primarily as a biological marker and mechanistic research target rather than an established therapeutic agent, with human studies actively characterizing its roles across multiple disease contexts.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

Thymosin Beta-15 (Tβ15) is a 44-amino acid peptide with a molecular weight of approximately 5,173 Da, belonging to the thymosin beta family of G-actin-binding and sequestering proteins5. Like all thymosin beta family members, Tβ15 contains the conserved LKKTET actin-binding motif that enables high-affinity interaction with monomeric globular actin (G-actin), preventing its polymerization into filamentous actin (F-actin)14. What distinguishes Tβ15 from other family members — notably Thymosin Beta-4 — is its demonstrated capacity to directly regulate cell motility in prostatic carcinoma cells, a function not shared by other thymosin beta proteins known at the time of its discovery3,14,17. This pro-migratory function is mechanistically linked to its actin-sequestering activity: by modulating the local availability of G-actin, Tβ15 influences the dynamic remodeling of the cytoskeleton required for lamellipodia formation and directional cell movement.

Two functionally distinct human gene paralogs have been characterized: TMSB15A and TMSB15B. These isoforms exhibit differential tissue expression patterns — TMSB15A predominates in prostate tissues while TMSB15B is more prominent in colon tissues — and are regulated independently at the transcriptional level. Transforming growth factor beta-1 (TGF-β1) selectively represses TMSB15A but not TMSB15B expression in breast cancer cell lines, and siRNA-mediated knockdown of TMSB15B suppresses EGF-induced prostate cancer cell migration, confirming independent functional contributions from each isoform4. This isoform distinction is critical for the interpretation of prior research, as earlier studies may have conflated both paralogs.

Beyond its oncological roles, Tβ15 has been identified as a regulator of thymic epithelial cell (TEC) spatial organization. Overexpression of Tβ15 inhibits chemotaxis of TECs toward the medullary compartment and blocks positive selection of thymocytes from CD4+CD8+ double-positive to CD4+ single-positive cells, while Tβ15 knockdown accelerates reticular TEC differentiation but paradoxically results in quantitatively higher yet functionally less mature peripheral T cell output6. The mechanism involves Tβ15's role in cytoskeletal actin dynamics within TECs — Ligustilide, a phytochemical compound, has been shown to competitively inhibit the Tβ15–G-actin complex, thereby promoting microfilament assembly and restoring normal TEC spatial patterning and T cell selection in models of thymic senescence7.

Tβ15 has additionally been proposed as a secondary endogenous precursor of the tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), sharing structural homology at the N-terminus with Thymosin Beta-4, which is the primary known Ac-SDKP precursor. Residual Ac-SDKP detected in Tβ4 knockout mice — including in kidney tubular segments where Tβ15 expression has been immunohistochemically confirmed — supports this precursor role, though direct biochemical confirmation of the cleavage pathway requires further investigation12. No published pharmacokinetic data — including half-life, bioavailability, or metabolic fate — are available for exogenous Tβ15 administration in mammals.

§04Evidence & efficacy

Evidence base
98Studies
38Human
17Animal

The efficacy evidence base for Thymosin Beta-15 is concentrated in its roles as a biological marker and mechanistic regulator rather than as an exogenous therapeutic agent. In the domain of cancer biomarker utility, high TMSB15A mRNA expression appears to predict pathological complete response (pCR) to neoadjuvant anthracycline/taxane chemotherapy in triple-negative breast cancer (TNBC), with approximately two- to three-fold differences in pCR rates observed between high- and low-expression groups across independent cohorts1,2. In prostate cancer, elevated Tβ15 protein expression may serve as a prognostic indicator of PSA failure and bone metastasis in patients with localized disease, with 5-year PSA failure-free survival reported at 25% for highest-staining versus 83% for lowest-staining groups9. Preclinical mechanistic evidence demonstrates that Tβ15 positively regulates tumor cell motility — antisense knockdown reduces cell migration in prostatic carcinoma models, and expression correlates with Gleason grade in human prostate cancer tissue3. In thymic biology, Tβ15 appears to regulate the spatial organization and differentiation of thymic epithelial cells, influencing the quality of T cell maturation6,7. Pro-angiogenic activity has been demonstrated in the CAM model at concentrations above 1 µg per disc5. No controlled therapeutic intervention trials evaluating exogenous Tβ15 administration for any indication have been published.

§05Safety

No formal human safety or tolerability data for exogenous Thymosin Beta-15 administration have been published. The compound has not advanced to human clinical trials as a therapeutic agent, meaning no adverse event profiles, maximum tolerated doses, or drug interaction data are available from human studies. In the single mammalian in vivo study involving Tβ15 modulation, mice implanted with Tβ15-knockdown thymic epithelial cells exhibited high thymic output but reduced peripheral T cell maturity and functional activity, suggesting that disruption of normal Tβ15 expression may produce functional immune alterations rather than overt toxicity6. A separate mouse study using Ligustilide — a compound that modulates Tβ15 activity indirectly — reported good tolerability at 5 mg/kg, with the compound ameliorating rather than causing adverse systemic effects such as weight loss and grip strength reduction7. No direct toxicity, inflammatory, or off-target organ effects attributable to Tβ15 itself were reported in these animal models. Tβ15 has been shown to exhibit pro-angiogenic activity in the CAM model5, and its endogenous upregulation is associated with increased tumor cell motility and metastatic phenotypes in prostate and breast cancer tissues3,9 — biological relationships that clinical safety research will continue to characterize as the field develops.

§06History

Thymosin Beta-15 was first identified and characterized in the mid-1990s through research into the molecular determinants of prostate cancer metastasis. The foundational discovery, reported by Bao, Loda, Zetter, and colleagues in 1996, identified Tβ15 as a gene markedly upregulated in highly motile and metastatic Dunning rat prostatic carcinoma cell lines and confirmed elevated expression in human prostate cancer tissues correlating with Gleason grade3. This work established Tβ15 as the first thymosin beta family member shown to directly regulate cell motility, distinguishing it functionally from previously characterized family members. Concurrent patent filings from Zetter and Bao between 1996 and 1997 described the human gene sequence and its diagnostic and prognostic potential across multiple cancers including prostate, lung, melanoma, and breast cancer15,16,17,18,19.

The early 2000s saw translation of these findings toward clinical biomarker validation. A 2000 pilot study in 32 prostate cancer patients demonstrated that Tβ15 staining intensity predicted PSA failure and bone metastasis following radiotherapy9, while a 2001 report described development of a urine-based ELISA for non-invasive Tβ15 detection in prostate cancer patients11. Structural and isoform complexity was substantially clarified in the late 2000s with the identification of the second human paralog TMSB15B and its independent transcriptional regulation by TGF-β14,8. Biomarker research expanded into breast cancer through the GeparTrio and GeparQuattro trials, where TMSB15A mRNA emerged as a predictor of chemotherapy response in TNBC1,2. More recently, investigations have uncovered a previously uncharacterized role for Tβ15 in thymic epithelial cell biology and immune senescence6,7, broadening the research landscape beyond oncology.

§07References